Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8025258 | 0.77 | HTT (0.34) | SMN1; SMN2HTTLMNACA1NPC1 | |
| SCHEMBL26087113 | 0.77 | — | — | |
| SCHEMBL667530 | 0.76 | CA1 (0.47) | SMN1; SMN2HTTLMNACA1NPC1 | |
| SCHEMBL9299929 | 0.75 | — | — | |
| SCHEMBL8023240 | 0.73 | CNR2 (0.33) | SMN1; SMN2HTTLMNA | |
| SCHEMBL666176 | 0.71 | — | — | |
| SCHEMBL4077299 | 0.71 | — | — | |
| SCHEMBL13056251 | 0.71 | LMNA (0.39) | SMN1; SMN2HTTLMNACA1NPC1 | |
| SCHEMBL1219896 | 0.71 | — | — | |
| SCHEMBL381097 | 0.69 | CA1 (0.56) | SMN1; SMN2HTTLMNACA1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102216279-A | Phenyl pyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof | TOPHARMAN SHANGHAI CO LTD | 2011-10-12 | — | — | CN | claimed |
| US-8399667-B2 | 4-anilino quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | disclosed |
| CN-102216279-A | Phenyl pyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof | TOPHARMAN SHANGHAI CO LTD | 2011-10-12 | — | — | CN | disclosed |
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | HENNEQUIN LAURENT FRANCOIS AND | 2009-12-17 | — | — | US | disclosed |
| US-7625908-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-7569577-B2 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-08-04 | — | — | US | disclosed |
| US-20080234263-A1 | Quinazoline Derivatives | ASTRAZENECA (SE) | 2008-09-25 | — | — | US | disclosed |
| US-20070244136-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | BRADBURY ROBERT H | 2007-10-04 | — | — | US | disclosed |
| EP-1756088-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005026151-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005026156-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005026152-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005026150-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| EP-1487806-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | Astrazeneca AB (SE) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082831-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
| US-6153734-A | A TETRAKISAZO DYE OR A POLYAZO DYE; GOOD WET AND PERSPIRATION FASTNESS PROPERTIES; DYEING COTTON, WOOL, POLYAMIDE AND ESPECIALLY LEATHER, PAPER PULP, ALSO HAIR OR FURS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-28 | — | — | US | disclosed |
| EP-0980405-A1 | OLIGOMER AZO COLORANTS | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998050470-A1 | OLIGOMER AZO COLORANTS | BASF AKTIENGESELLSCHAFT (DE) | 1998-11-12 | — | — | WO | disclosed |
| EP-0430004-A2 | 1,8-Naphthalimides as antidotes | BASF Aktiengesellschaft (DE) | 1991-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ERBB2, ABL1, EGFR | SMN1; SMN2 4670/4885HTT 4428/4885LMNA 3304/4885 |
| US-20080234263-A1 | Quinazoline Derivatives | EGFR, ERBB2, ERBB3 | SMN1; SMN2 4803/4885HTT 4291/4885LMNA 3059/4885 |
| US-20070244136-A1 | Quinazoline Derivatives | ERBB2, ABL1, MKI67 | SMN1; SMN2 3023/4885HTT 3936/4885LMNA 3865/4885 |
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | ERBB2, ERBB3, ERBB4 | SMN1; SMN2 4594/4885HTT 3380/4885LMNA 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.